Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Kimberly-Clark shares declined marginally in the premarket session on Tuesday, after a sharp drop the previous day. ・The ...

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO& ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...

Kenvue › Kimberly-Clark (NASDAQ: KMB) has agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock deal, valuing Kenvue at ...

Kimberly-Clark has agreed to acquire Kenvue Inc. in a cash-and-stock transaction valuing the consumer health company at ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

More gains for Nvidia, Amazon and other AI superstars propped up Wall Street on Monday. The S&P 500 rose 0.2% and pulled closer to its all-time high set last week, even though the majority of stocks ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...